Anti-TP53I13 Polyclonal Antibody for WB, IF/ICC, ELISA - Q8NBR0

Core Product Specifications and Parameters

Biological Background: TP53I13 Function and Localization

• TP53I13 (tumor protein p53-inducible protein 13), also referred to as damage-stimulated cytoplasmic protein 1 (DSCP1), is a p53-responsive protein implicated in tumor suppression.
• Overexpression of TP53I13 inhibits tumor cell growth, suggesting a functional role in negatively regulating proliferation.
• The protein localizes to both the cell membrane and the cytoplasm, consistent with its predicted signal peptide and transmembrane domain.
• TP53I13 is broadly expressed across human tissues, including heart, placenta, skeletal muscle, testis, brain, and lung.
• As a reference proteome member with transmembrane features, TP53I13 may participate in membrane-associated signaling or stress responses.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 180–310 of human TP53I13; ensure the target epitope is present in your experimental system.
• For Western blot, a band near 42 kDa is expected under reducing conditions; validate molecular weight with appropriate controls.
• In immunofluorescence/immunocytochemistry, anticipate membrane and cytoplasmic localization; optimize fixation and permeabilization protocols for your cell type.
• Cross-reactivity with mouse and rat enables multi-species studies; verify reactivity in your specific strain or tissue.
• For ELISA, titrate the antibody and include relevant positive/negative controls to establish assay specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is a dedicated one-stop sourcing partner for IVD raw materials, connecting diagnostic developers and researchers with high-quality reagents like this anti-TP53I13 polyclonal antibody for tumor biology studies. We offer a broad portfolio including validated antibody pairs, optimized monoclonal and polyclonal antibodies, ancillary reagents, and customized sourcing for rare targets, supporting every stage from concept to clinic.